Drugmakers have long relied on their ability to charge whatever they deemed appropriate in the U.S., the world’s most expensive healthcare system. Pascal Soriot, chief executive of AstraZeneca Plc (AZN.L), warned investors that the pressure exerted by health insurers has expanded from medicines used to treat common maladies to the specialized fields, like cancer, where drugmakers have been able to charge their highest prices. Many say the tide shifted with a campaign by insurers and pharmacy benefits companies against Gilead Sciences Inc’s (GILD.O) $84,000 hepatitis C treatment Sovaldi.
Published in TZ Latest News 14 January, 2015 by The TZ Newswire Staff
Insight: Big Pharma faces up to new price pressure from aggressive insurers
Published in TZ Latest News 14 January, 2015 by The TZ Newswire Staff
Insight: Big Pharma faces up to new price pressure from aggressive insurers
Drugmakers have long relied on their ability to charge whatever they deemed appropriate in the U.S., the world’s most expensive healthcare system. Pascal Soriot, chief executive of AstraZeneca Plc (AZN.L), warned investors that the pressure exerted by health insurers has expanded from medicines used to treat common maladies to the specialized fields, like cancer, where drugmakers have been able to charge their highest prices. Many say the tide shifted with a campaign by insurers and pharmacy benefits companies against Gilead Sciences Inc’s (GILD.O) $84,000 hepatitis C treatment Sovaldi.